European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim, Samsung Bioepis ...
The patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a host of cheaper biosimilars to hit the market. Sales of AbbVie’s Humira (adalimumab) reached $4.4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback